Application of AE as medicine for preventing and treating hyperlipemia

A blood lipid-lowering drug and technology for hyperlipidemia, applied in the field of medicine

Inactive Publication Date: 2019-05-03
TIANJIN UNIV OF SCI & TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no report about 8-C-Asorbyl-(-)-Epigallocatechin acting on PTP-1B signaling pathway and preventing and treating hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of AE as medicine for preventing and treating hyperlipemia
  • Application of AE as medicine for preventing and treating hyperlipemia
  • Application of AE as medicine for preventing and treating hyperlipemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Application of a natural product AE (8-C-Asorbyl-(-)-Epigallocatechin) as a regulator of protein tyrosine phosphatase 1B signaling pathway in the prevention and treatment of hyperlipidemia

[0026] 1. Experimental materials

[0027] 4-Nitrophenylphosphate disodium salt (pNPP), NaVO 4 , purchased from Sigma-Aldrich (St.Louis, MO); recombinant human PTP-1B protein was purchased from Abcam (Cambridge, UK); CHO-K1 cells were obtained from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China).

[0028] Male Kunming mice (18–22 g) were provided by the Experimental Animal Center of the Academy of Medical Sciences of the Chinese People’s Liberation Army, approved by the local Animal Protection Bureau, and strictly abided by local and national ethical guidelines. Mice were kept in polypropylene cages (5 per cage) and raised under laboratory conditions (18-23° C., 55-60% humidity, 12-hour light-dark cycle), and all mice had free access to foo...

Embodiment 2

[0056] Application of 8-C-Asorbyl-(-)-Epigallocatechin

[0057] For the preparation of blood lipid-lowering drugs, including the active ingredient 8-C-Asorbyl-(-)-Epigallocatechin, and pharmaceutically acceptable carriers or excipients, made into pharmaceutically acceptable dosage forms. The pharmaceutically acceptable carrier or Excipients include one or more solid, semi-solid or liquid excipients; pharmaceutically acceptable dosage forms include tablets, capsules, granules, injections, pills, syrups, powders, ointments, liquid preparations and the like.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a natural product small molecule AE for preparing a medicine for preventing and treating hyperlipemia diseases. The study results indicate that AE can up-regulate the phosphorylation levels of GSK-3beta and Akt protein on a PTP-1B signaling pathway, thereby can down-regulate the protein level of PTP-1B, can inhibit the activity of PTP-1B, and plays a role in the prevention and treatment of hyperlipidemia. As a natural sourced novel PTP-1B signaling pathway regulator, AE has a good application prospect.

Description

technical field [0001] The present invention relates to the medicinal use of AE (8-C-Asorbyl-(-)-Epigallocatechin), an active ingredient of natural products, in particular to the use of AE (8-C-Asorbyl-(-)-Epigallocatechin) in preventing and treating hyperlipidemia The application in the invention belongs to the field of medicine. technical background [0002] 8-C-Asorbyl-(-)-Epigallocatechin (Formula 1) was first extracted and isolated from oolong tea by Itsuo Nishioka's research group in 1989. In 2013, Yang Zhen's research group synthesized catechin and vitamin C for the first time. Studies have shown that 8-C-Asorbyl-(-)-Epigallocatechin has many health care and pharmacological effects on the human body, such as inhibiting pancreatic lipase, anti-HIV, and anti-tumor effects. [0003] [0004] Chemical structure of formula 1 AE (8-C-Asorbyl-(-)-Epigallocatechin) [0005] Insulin can promote the synthesis and storage of fat, reduce the free fatty acid in the blood, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P3/06
Inventor 孙华郁彭金宗鑫陈明珠芦逵陶云昌王朝昕吴岩汪海波
Owner TIANJIN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap